PIK3CA Gene Mutation

Drug	Drug Name	Drug Description
DB12015	Alpelisib	Alpelisib is indicated in combination with fulvestrant to treat postmenopausal women, and men, with advanced or metastatic breast cancer. This cancer must be hormone receptor (HR)-positive, human epidermal growth factor...
DB00947	Fulvestrant	An estrogen receptor antagonist used to treat HR+ breast cancer that may also be HER2-.

Drug	Drug Name	Target	Type
DB12015	Alpelisib	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	target
DB12015	Alpelisib	Cytochrome P450 3A4	enzyme
DB12015	Alpelisib	Cytochrome P450 2C9	enzyme
DB12015	Alpelisib	Cytochrome P450 2C8	enzyme
DB12015	Alpelisib	Cytochrome P450 2C19	enzyme
DB12015	Alpelisib	ATP-binding cassette sub-family G member 2	transporter
DB12015	Alpelisib	P-glycoprotein 1	transporter
DB00947	Fulvestrant	Estrogen receptor alpha	target
DB00947	Fulvestrant	Cytochrome P450 3A4	enzyme
DB00947	Fulvestrant	UDP-glucuronosyltransferase 1-1	enzyme

Drug	Drug Name	Phase	Status	Count
DB12015	Alpelisib	1 / 2	Active Not Recruiting	1
DB01101	Capecitabine	1 / 2	Active Not Recruiting	1